AIRR Community 2021 Plans Ratification Vote!
Voting is now closed.
Vote by December 4th! AIRR-C Executive SC 2020 Election
AIRR-C Executive SC 2020 Election – It’s Time to Vote!!
With each major meeting interval of the AIRR Community, elections are held for leadership positions within the AIRR-C Executive Sub-committee. This year, per our governance, we have sought nominations for Executive SC Chair-Elect and up to three members of the Executive SC. We are pleased to announce that we have a strong set of candidates and we are grateful to all the nominees for letting their name stand.
How to Vote:
Voting is now complete. Results are available here.
Election Timeline:
Voting opens: November 24, 2020
Polls close: December 4, 2020
Voting results announced: December 10, 2020 (last day of the AIRR-C meeting)
Thank you for all of the time you give to the AIRR Community and for participating in this election!
FDA approves naxitamab-gqgk (DANYELZA®)
On November 25, 2020, Y-mAbs announced that the FDA approved naxitamab-gqgk (DANYELZA®) 40mg/10ml in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. The approval for this indication was granted under FDA’s accelerated approval regulations based on the overall response rate and duration of response.
Naxitamab, a humanized anti-GD2 IgG1k antibody was developed by Memorial Sloan Kettering Cancer Center and licensed to Y-mAbs Therapeutics. FDA granted Breakthrough Therapy and Rare Pediatric Drug designations to naxitamab for the treatment of patients with neuroblastoma, and naxitamab was granted Orphan Drug designations in the EU and US for this indication.
DANYELZA® is the 10th antibody therapeutic to be granted a first approval in the US or EU in 2020.
The Antibody Society maintains a comprehensive table of approved monoclonal antibody therapeutics and those in regulatory review in the EU or US. The table, which is located in the Web Resources section of the Society’s website, can be downloaded in Excel format.
Register now for Pre-Meeting “AIRR-seq in the Pandemic!
AIRR-seq in the Pandemic:
AIRR Community/Tsinghua University Joint Meeting
A pre-meeting to AIRR-C Meeting V: Zooming in to the AIRR Community!
We are pleased to announce a meeting co-organized by the AIRR Community and Tsinghua University, which will mainly focus on Chinese researchers using AIRR-seq data to study the adaptive immune response, especially in COVID-19 patients. This event has been scheduled as a pre-meeting for the regular AIRR Community Meeting V: “Zooming in to the AIRR Community” which will be held virtually December 8-10th, 2020. Professor Xiao Liu of Tsinghua University is organizing an in-person meeting of Chinese researchers in Shenzen, China on Sunday December 6, 2020, and researchers from North America and Europe will join this group virtually.
The Timeline:
The in-person meeting will convene all day Sunday, December 6th, 2020 in Shenzhen, China. North American researchers will virtually introduce the AIRR-seq Community approach and present research on COVID-19 during the evening of Saturday, December 5th, including a welcome by the Chair of the AIRR Community Executive Sub-committee, Dr. Nina Luning Prak; Saturday evening in North America will correspond to the morning of Sunday, December 6th in Shenzhen. In addition, on the morning of Sunday, December 6th in Europe, two members of the AIRR Community will join from Europe, including Victor Greiff; this will correspond to the afternoon of December 6th in Shenzhen. See the draft agenda below for further details on this complicated enterprise! And please join us if you can, in this international effort to integrate this important sector of the immunogenetics community more closely with the AIRR Community
For complete details and agenda visit the Pre-Meeting web page.
This virtual meeting is free but registration is required.